Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Deuruxolitinib Bioavailability in Healthy Volunteers
NCT05467696Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuruxolitinib in alopecia areata (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 6, Time to Maximum Plasma Concentration at Day 6 and 2 more. Started Jun 2022; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05467696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467696.